Helical offers a platform that turns biological foundation model outputs into reproducible, decision-ready in-silico workflows via two main components: the Virtual Lab for biologists and translational scientists, and the Model Factory for machine learning engineers and data scientists. Its platform integrates computational predictions with biological validation, enabling shared data, models, and results to facilitate collaboration across traditionally siloed teams. The company reports working with several top-20 global pharmaceutical companies and supporting reductions in discovery timelines across target identification, biomarker discovery, and therapeutic design. Helical was founded in early 2024 by Rick Schneider, Maxime Allard, and Mathieu Klop. Financially, it has just completed a $10 million seed round to expand deployments and enhance the platform’s evidence layer.

Total raised

$12M

Funding rounds

2

Latest round

Seed

Latest activity

Apr 2026